ProgenaBiome Newsroom - Profile and News Archive

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, ProgenaBiome has 42+ ongoing clinical trials related to immunity and disease with six COVID-19 studies validating testing, prophylaxis, and treatment protocols for the novel coronavirus.

Engage with ProgenaBiome

Learn more online at: https://progenabiome.com/

Follow:   |  Facebook  |  LinkedIn

RSS News Feed for ProgenaBiome

Press Releases from ProgenaBiome :

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2

VENTURA, Calif., Oct. 26, 2020 (SEND2PRESS NEWSWIRE) — The American College of Gastroenterology (ACG) named Progenabiome “Outstanding Poster Presenter” for its poster: “Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection,” which will be presented virtually at the ACG Annual Scientific Meeting this week.

Alzheimer’s Patient Recalls Daughter’s Birthday After Undergoing Fecal Transplant

Malibu Microbiome Meeting 2021

VENTURA, Calif., Oct. 7, 2020 (SEND2PRESS NEWSWIRE) — Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer’s disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT).